A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
作者信息
Sheremata W A, Vollmer T L, Stone L A, Willmer-Hulme A J, Koller M
机构信息
University of Miami, Department of Neurology, School of Medicine, FL 33136, USA.
出版信息
Neurology. 1999 Mar 23;52(5):1072-4. doi: 10.1212/wnl.52.5.1072.
PMID:10102433
Abstract
A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
摘要
Zotero 插件